New Invention Profile
| Publication No: | IN202211050486 [India] | Application No: | 202211050486 |
| Title: | RAS binding peptides as selective inhibitors of mtor signaling complex-2 | ||
| Publication Date: | 08-03-2024 | File Date: | 02-09-2022 |
| Inventor(s): | Wahajul Haq; Smrati Bhadauria; Deepali Pandey; Javed Miyan; Varsha Singh; Narayan Kumar Goswami; Ashish Arora; Jiaur Rahaman Gayen; Sarita Tripathi; Damodara Reddy Nandarapu; Jhajhan Lal | ||
| IPC Classification: | A61B10/00, C07D417/12, H02J7/02, H01L51/50, A47G19/22 | ||
| Abstract: | The present invention relates to the discovery of small synthetic peptides exhibiting Ras binding ability. The peptides are designed from the Ras binding domain of mSIN1 responsible for binding to Ras for specific upregulation of mTOR complex-2. The synthetic Ras binding peptides have the ability to perturb the binding of Ras with endogenous mSIN1 as a result of competitive binding. These peptides are first-in-class, selective mTOR complex-2 inhibitors excluding any effect on mTOR complex-1. The novel Ras binding peptides are stable to proteases and able to penetrate into the cell as demonstrated using FITC/Rhodamine tagged peptide in cell culture assay. These Ras- binding peptides have demonstrated a unique property of arresting cell migration and invasion which are two critical cellular processes being regulated by mTORC2. These inhibitory effects of candidate peptide(s) were also replicated in in vivo studies conducted in the syngenic 4T1/BalbC, orthotopic mouse model of breast cancer. Thus, the invention provides novel Ras binding peptides as first-in- class mTOR complex-2 inhibitors that not only selectively inhibit mTORC2 signaling and ensuing processes in vitro but in vivo as well. | ||
CSIR-Central Drug Research Institute[CSIR-CDRI]
: director[at]cdri[dot]res[dot]in
:91-522-2772450
:https://www.cdri.res.in
: director[at]cdri[dot]res[dot]in
:91-522-2772450
:https://www.cdri.res.in
Industrial Applications
Others [ROOT]